Dr. Sampson Abu is a board-certified medical optometrist and glaucoma researcher who consults for pharmaceutical and medtech organizations on glaucoma progression, OCT diagnostics, and ocular disease management. He is available for advisory boards, speaking engagements, and consulting projects.
Dr. Sampson L. Abu is a board-certified medical optometrist based in Athens, Georgia, with a clinical focus on glaucoma, dry eye disease, neuro-ophthalmic conditions, and vascular ocular disease. He manages complex ocular disease at Thomas Eye Center and brings that patient care perspective directly to his consulting work.
His postdoctoral research at the University of Alabama at Birmingham was NIH-funded and focused on novel strategies for early detection of glaucoma progression, including individualized structure-function models, postprocessed visual field analysis, and real-world medication adherence in glaucoma patients. He trained under Dr. Lyne Racette, one of the leading researchers in glaucoma perimetry.
His work has appeared in Ophthalmology, Translational Vision Science and Technology, Scientific Reports, Journal of Glaucoma, PLOS ONE, and more than a dozen other peer-reviewed journals. He has presented original research at ARVO, the World Glaucoma Congress in Helsinki, the North American Perimetric Society, and multiple American Academy of Optometry annual meetings. He reviews manuscripts for Investigative Ophthalmology and Vision Science, the British Journal of Ophthalmology, and several other journals.
Dr. Abu was born in Ghana and completed his optometry training across three countries before his postdoctoral fellowship in the United States. For pharmaceutical companies thinking about diverse patient populations, health equity data, or sub-Saharan African markets, that background is directly relevant. His published work includes research on glaucoma medication adherence conducted in Ghana, one of very few studies of its kind from that region.
His research informs his clinical decisions, and his clinical practice keeps his research grounded. That feedback loop is what makes his consulting input different from what you get from a full-time academic or a retired clinician.
Active peer reviewer for Investigative Ophthalmology and Vision Science, the British Journal of Ophthalmology, Ophthalmic and Physiological Optics, Scientific Reports, and the Journal of Optometry. Over 25 manuscripts reviewed.
Dr. Abu is an experienced scientific presenter who has spoken at international glaucoma and optometry conferences across North America, Europe, and Africa. He is available for pharmaceutical industry symposia, medical education programs, conference keynotes, and clinical advisory panels. His presentations are research-grounded and he is comfortable adjusting the level of detail for audiences ranging from specialist researchers to clinical affairs and commercial teams.
Dr. Sampson L. Abu is a board-certified medical optometrist and NIH-funded glaucoma researcher based in Athens, Georgia. He completed a postdoctoral fellowship at the University of Alabama at Birmingham, where his research focused on early detection of glaucoma progression using structure-function modeling, OCT analytics, and visual field analysis. He is a Fellow of the American Academy of Optometry and a Diplomate of the American Board of Optometry, with more than 16 peer-reviewed publications and presentations at ARVO, the World Glaucoma Congress, and the American Academy of Optometry. He practices at Thomas Eye Center in Athens, Georgia.
This bio may be used in conference programs and event materials.Attendees leave with a clear picture of where current detection methods fall short and what combining structural and functional data actually changes for clinical decision-making and trial design.
Practical criteria for assessing new ophthalmic diagnostics. Useful for product and clinical affairs teams that need a clinician's view on what makes a tool viable in real practice.
Published findings on adherence patterns, pandemic disruption, and racial disparities — and what they mean for how drugs are designed, packaged, and supported in the real world.
A frank look at what RNFL and visual field metrics reliably measure, where they disagree, and what that means for anyone using them as endpoints or marketing claims.
Dr. Abu works with pharmaceutical and medical device organizations that need a clinical expert in glaucoma and ocular disease. His value is specific: he sees glaucoma patients in clinic, has published original research on glaucoma progression and diagnostic methods, and understands what the science actually looks like in practice. Companies working on glaucoma drugs, diagnostic devices, or patient adherence programs hire that combination.
Industry track record: Dr. Abu's research on glaucoma medication adherence was selected for the Roche Collaborative Research Award through ARVO, recognizing industry-relevant scientific contributions in ocular disease.
Clinical review of OCT devices, visual field software, and diagnostic analytics for product validation, regulatory support, and market positioning.
Clinical and research perspective on progression monitoring, structural and functional endpoints, and the practical limits of current diagnostic tools.
Input on study protocols, primary and secondary endpoints, patient selection criteria, and methodological considerations for glaucoma and ocular disease trials.
Ongoing participation as a clinical advisor or scientific reviewer for pharmaceutical and device programs in glaucoma and ocular disease.
Clinical accuracy review of educational materials, manuscripts, promotional content, and monographs related to glaucoma and ophthalmic therapeutics.
Research-based perspective on glaucoma adherence patterns, patient behavior, and what published data suggests for drug formulation, packaging, and support programs.
Interested in working together?Dr. Abu takes on a limited number of consulting engagements. Reach out to discuss scope, availability, and fit.
Start a ConversationEngagement formats: Dr. Abu is available for single advisory sessions, ongoing retainer arrangements, and project-based engagements. This includes one-time expert network calls, multi-session advisory board participation, manuscript and content review, and longer-term consulting relationships.
For speaking invitations, consulting inquiries, advisory board opportunities, or media requests, use the form or reach out directly by email. Dr. Abu reviews all inquiries personally and typically responds within 48 hours.
Typically responds within 48 hours.